Clinical Trial: Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

Sponsor and Collaborators
Threshold Pharmaceuticals

Contact
Esther Chu
650-474-8281

Principal Investigator
Jeffrey Matous, MD
Colorado Blood Cancer Institute

Kenneth Shain, MD
Moffitt Cancer Center

Irene Ghobrial, MD
Dana-Farber Cancer Institute

ClinicalTrials.gov Identifier 
NCT01522872

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs